Literature DB >> 15126144

Photodynamic therapy of subfoveal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis.

Bernadette Snyers1, Claire Verougstraete, Laurence Postelmans, Anita Leys, Philip Hykin.   

Abstract

PURPOSE: To evaluate the effect of photodynamic therapy on subfoveal neovascular membrane related to type 2A idiopathic juxtafoveolar retinal telangiectasia.
DESIGN: Interventional case series.
METHODS: Retrospective review of four eyes of four patients who underwent photodynamic therapy for subfoveal neovascular membrane secondary to idiopathic juxtafoveolar retinal telangiectasia. Ocular photodynamic therapy with verteporfin was performed in all cases using standard protocols. Results are given in terms of final visual acuity and neovascular membrane activity based on clinical examination, fluorescein and indocyanin green angiography, and, in two cases, optical coherence tomography.
RESULTS: Baseline visual acuity of 20/30 and 20/40 (x2) was maintained in three patients after one, two, and three sessions of photodynamic therapy respectively, and a follow-up of 23, 21, and 9 months. Leakage specific to the subfoveal neovascular membrane ceased on the fluorescein angiography. In the other patient, the final vision decreased from 20/50 to 20/200 after four sessions of photodynamic therapy and a follow-up of 14 months. Although there was still mild persistent leakage on the fluorescein angiography, neovascular membrane size was unchanged, and no subretinal fluid was demonstrated on optical coherence tomography.
CONCLUSIONS: Data from this case series suggest that photodynamic therapy may be effective in managing subfoveal neovascular membrane associated with idiopathic juxtafoveolar retinal telangiectasia, which usually carries a poor visual prognosis. Prospective study is required to confirm the beneficial effect of this treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15126144     DOI: 10.1016/j.ajo.2003.11.076

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  13 in total

1.  Treatment frequency and visual outcome in subfoveal choroidal neovascularization related to pathologic myopia treated with photodynamic therapy.

Authors:  Noémi Maár; Erdem Ergun; Alexandra Luksch; Michael Stur
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-15       Impact factor: 3.117

2.  Intravitreal ranibizumab as primary treatment for neovascular membrane associated with idiopathic juxtafoveal retinal telangiectasia.

Authors:  Lazaros Konstantinidis; Irmela Mantel; Leonidas Zografos; Aude Ambresin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-11       Impact factor: 3.117

3.  Intravitreal anti-VEGF treatment for subretinal neovascularisation secondary to type 2 idiopathic juxtafoveolar telangiectasia.

Authors:  Teresa Barth; Florian Zeman; Horst Helbig; Maria-Andreea Gamulescu
Journal:  Int Ophthalmol       Date:  2017-01-21       Impact factor: 2.031

4.  Subretinal neovascular membrane associated with type 2a idiopathic juxtafoveolar telangiectasis in pseudoxanthoma elasticum.

Authors:  Maurizio Battaglia Parodi; Pierluigi Iacono; Giuseppe Ravalico
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-09-19       Impact factor: 3.117

5.  One-year results of verteporfin therapy for subretinal neovascularization associated with type 2A parafoveal telengiectasia.

Authors:  Nazimul Hussain; Taraprasad Das; Rohit Khanna; L S Mohan Ram; Kallukuri Sumasri
Journal:  Clin Ophthalmol       Date:  2007-12

6.  Idiopathic juxtafoveolar retinal telangiectasis: a current review.

Authors:  Sawsan R Nowilaty; Hanan N Al-Shamsi; Wajeeha Al-Khars
Journal:  Middle East Afr J Ophthalmol       Date:  2010-07

Review 7.  Macular telangiectasia type 2.

Authors:  Peter Charbel Issa; Mark C Gillies; Emily Y Chew; Alan C Bird; Tjebo F C Heeren; Tunde Peto; Frank G Holz; Hendrik P N Scholl
Journal:  Prog Retin Eye Res       Date:  2012-12-03       Impact factor: 21.198

8.  [Therapeutic approaches for macular telangiectasia type 2: status quo and perspectives].

Authors:  F G Holz; T F C Heeren; E Krüger; M Zeimer; D Pauleikhoff; P Charbel Issa
Journal:  Ophthalmologe       Date:  2014-09       Impact factor: 1.059

9.  Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia.

Authors:  Subrata Mandal; Pradeep Venkatesh; Zahir Abbas; Rajpal Vohra; Satpal Garg
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-03-08       Impact factor: 3.117

10.  A case of subretinal neovascularization treated with intravitreal ranibizumab in a patient with idiopathic juxtafoveal retinal telangiectasis.

Authors:  Dimitrios Karagiannis; Ilias Georgalas; Ioannis Ladas; Parikakis Eustratios; Panagiotis Mitropoulos
Journal:  Clin Interv Aging       Date:  2009-05-14       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.